Inductive Bio
Inductive Bio embeds frontier AI, lab robotics, and expert chemists into small-molecule drug discovery via Compass, Indy, and Beacon-2.
Founded
2021Inductive Bio embeds frontier AI, lab robotics, and expert chemists into small-molecule drug discovery via Compass, Indy, and Beacon-2.
Inductive Bio won three consecutive blind OpenADMET prediction challenges, giving its dose and ADMET models independent benchmark credibility. A pre-competitive consortium data network compounds partner data into shared predictive power that single-tenant tools cannot match.
Program-level fine-tuning adapts the models to each customer chemical series, and a peer-reviewed Nested Therapeutics collaboration documents fewer synthesized compounds to reach leads. Traction with Denali and Amgen signals enterprise confidence in the platform.
Source: inductive.bio
Inductive Bio operates as a chemical-intelligence company selling an enterprise and consortium platform to biopharma discovery teams. The business model combines software access to Compass and Indy with data-network participation and fee-based ADME and synthesis services.
The company has raised about 29.3 million dollars across seed and Series A rounds and employs an 11 to 50 person team supporting dozens of active drug programs. Pricing is not publicly disclosed, so evaluation rests on benchmark wins, consortium growth, and enterprise adoption.
Source: inductive.bio
Inductive Bio offers Compass, a virtual bench that pairs predictive ADMET models with expert medicinal chemistry support for small-molecule programs. Indy acts as an AI chemistry assistant that answers design questions inside the same workflow.
Beacon-2 predicts dose and human pharmacokinetics from early data, while ADME-One delivers high-throughput assays with AI-projected human PK. An AI-integrated synthesis service closes the loop from design to tested compounds.
Source: inductive.bio